Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2026
Reporting Period: Second quarter ended June 30, 2026
Business Context: The filing serves as a notification that the company issued a press release detailing its financial results for the specified quarter. The press release is attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. The filing explicitly states that the detailed results are contained in the attached press release (Exhibit 99.1), which is not included in the input text. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
No material changes regarding financial performance or operations are described in the text of this Form 8-K. The document solely references the issuance of the press release containing the results.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These items, if present, would be located in the attached press release (Exhibit 99.1) which is not part of the provided input.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for actual Q2 2026 financial figures.
- Verify the company's stock trading symbol (HALO) on The Nasdaq Stock Market LLC.
- Confirm the filing date of August 6, 2026, aligns with the company's standard reporting schedule.
- Check for any subsequent filings that may provide updated guidance or risk disclosures.